Skip to main content
Journal cover image

Individualizing duration of antibiotic therapy in community-acquired pneumonia.

Publication ,  Journal Article
Aliberti, S; Ramirez, J; Giuliani, F; Wiemken, T; Sotgiu, G; Tedeschi, S; Carugati, M; Valenti, V; Marchioni, M; Camera, M; Piro, R; Milani, G ...
Published in: Pulm Pharmacol Ther
August 2017

International experts suggest tailoring antibiotic duration in community-acquired pneumonia (CAP) according to patients' characteristics. We aimed to assess the effectiveness of an individualized approach to antibiotic duration based on time in which CAP patients reach clinical stability during hospitalization. In a multicenter, non-inferiority, randomized, controlled trial hospitalized adult patients with CAP reaching clinical stability within 5 days after hospitalization were randomized to a standard vs. individualized antibiotic duration. In the Individualized group, antibiotics were discontinued 48 h after the patient reached clinical stability, with at least five days of total antibiotic treatment. Early failure within 30 days was the primary composite outcome. 135 patients were randomized to the Standard group and 125 to the Individualized group. The trial was interrupted by the safety committee because of an apparent inferiority of the Individualized group over the Standard treatment: 14 (11.2%) patients in the Individualized group experienced early failure vs. 10 (7.4%) patients in the Standard group, p = 0.200, at the intention-to-treat analysis. 30-day mortality rate was four-time higher in the Individualized group than the Standard group. Shortening antibiotic duration according to patients' characteristics still remains an open question.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pulm Pharmacol Ther

DOI

EISSN

1522-9629

Publication Date

August 2017

Volume

45

Start / End Page

191 / 201

Location

England

Related Subject Headings

  • Time Factors
  • Respiratory System
  • Precision Medicine
  • Pneumonia, Bacterial
  • Middle Aged
  • Male
  • Humans
  • Hospitalization
  • Follow-Up Studies
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Aliberti, S., Ramirez, J., Giuliani, F., Wiemken, T., Sotgiu, G., Tedeschi, S., … Blasi, F. (2017). Individualizing duration of antibiotic therapy in community-acquired pneumonia. Pulm Pharmacol Ther, 45, 191–201. https://doi.org/10.1016/j.pupt.2017.06.008
Aliberti, Stefano, Julio Ramirez, Fabio Giuliani, Timothy Wiemken, Giovanni Sotgiu, Sara Tedeschi, Manuela Carugati, et al. “Individualizing duration of antibiotic therapy in community-acquired pneumonia.Pulm Pharmacol Ther 45 (August 2017): 191–201. https://doi.org/10.1016/j.pupt.2017.06.008.
Aliberti S, Ramirez J, Giuliani F, Wiemken T, Sotgiu G, Tedeschi S, et al. Individualizing duration of antibiotic therapy in community-acquired pneumonia. Pulm Pharmacol Ther. 2017 Aug;45:191–201.
Aliberti, Stefano, et al. “Individualizing duration of antibiotic therapy in community-acquired pneumonia.Pulm Pharmacol Ther, vol. 45, Aug. 2017, pp. 191–201. Pubmed, doi:10.1016/j.pupt.2017.06.008.
Aliberti S, Ramirez J, Giuliani F, Wiemken T, Sotgiu G, Tedeschi S, Carugati M, Valenti V, Marchioni M, Camera M, Piro R, Del Forno M, Milani G, Faverio P, Richeldi L, Deotto M, Villani M, Voza A, Tobaldini E, Bernardi M, Bellone A, Bassetti M, Blasi F. Individualizing duration of antibiotic therapy in community-acquired pneumonia. Pulm Pharmacol Ther. 2017 Aug;45:191–201.
Journal cover image

Published In

Pulm Pharmacol Ther

DOI

EISSN

1522-9629

Publication Date

August 2017

Volume

45

Start / End Page

191 / 201

Location

England

Related Subject Headings

  • Time Factors
  • Respiratory System
  • Precision Medicine
  • Pneumonia, Bacterial
  • Middle Aged
  • Male
  • Humans
  • Hospitalization
  • Follow-Up Studies
  • Female